Evidence map›Paper›PMID 33880466›Full record

ArticleResearch square2021

Rapid Identification of Druggable Targets and the Power of the PHENotype SIMulator for Effective Drug Repurposing in COVID-19.

Naomi I Maria, Rosaria Valentina Rapicavoli, Salvatore Alaimo, Evelyne Bischof, Alessia Stasuzzo, Jantine A C Broek, Alfredo Pulvirenti, Bud Mishra, Ashley J Duits, Alfredo Ferro

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Naomi I Maria *Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA.
Rosaria Valentina Rapicavoli *Department of Physics and Astronomy, University of Catania.
Salvatore Alaimo *Bioinformatics Unit, Department of Clinical and Experimental Medicine, University of Catania, Italy.
Evelyne BischofDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Via Pansini, Naples, Italy.
Alessia StasuzzoDepartment of Chemical Sciences, University of Catania, Italy.
Jantine A C BroekDepartment of Computer Science, Mathematics, Engineering and Cell Biology, Courant Institute, Tandon and School of Medicine, New York University, New York, USA.
Alfredo PulvirentiBioinformatics Unit, Department of Clinical and Experimental Medicine, University of Catania, Italy.
Bud Mishra *Department of Computer Science, Mathematics, Engineering and Cell Biology, Courant Institute, Tandon and School of Medicine, New York University, New York, USA.
Ashley J Duits *Red Cross Blood Bank Foundation Curaçao, Willemstad, Curaçao.
Alfredo Ferro *Bioinformatics Unit, Department of Clinical and Experimental Medicine, University of Catania, Italy.
University of Catania · ITCourant Institute of Mathematical Sciences · USFeinstein Institute for Medical Research · USNew York University · USShanghai University of Medicine and Health Sciences · CN

Funding

Topology of Cancer Evolution and HeterogeneityU54CA193313 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI IAVARONE, ANTONIO, RABADAN, RAUL · 2015 to 2020
$10.4M
NCI NIH HHS U54 CA193313
6 · The paper itself

Abstract

The current, rapidly diversifying pandemic has accelerated the need for efficient and effective identification of potential drug candidates for COVID-19. Knowledge on host-immune response to SARS-CoV-2 infection, however, remains limited with very few drugs approved to date. Viable strategies and tools are rapidly arising to address this, especially with repurposing of existing drugs offering significant promise.

Identifiers

PMID33880466
PMCPMC8057245
OpenAlexW3153770359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.